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Hypertrophic scarring is a skin disorder that occurs
after wounding and thermal injury. There is accumu-
lating evidence that immunologic processes such as
infiltration of activated T lymphocytes and altered
cytokine production may play a role in the formation
of hypertrophic scars. Interleukin-15, a cytokine
identified as a T cell growth factor, also acts as a
chemoattractant for T cells and has pro-inflammatory
properties. We investigated the expression and the
role of this cytokine in hypertrophic scarring. IL-15
expression was compared in skin biopsies of hyper-
trophic scars (HS) both in active (AHS) and in
remission (RHS) phases, in normotrophic scars (NTS)
and in normal skin using reverse transcriptase-poly-
merase chain reaction and immunohistochemistry.
IL-15 expression in HS was significantly higher than
in NTS or normal skin. Furthermore, AHS expressed
higher levels of IL-15 than RHS. Immunohistologic
Hypertrophic scars (HS) are the result of alterationsof the normal wound healing processes, character-ized by a protracted production of collagen, hyper-plasia, and increased cell turnover (Linares, 1996).Their typical clinical aspects (erythema, pain, dysae-
sthesia, pruritus, elevation) show all the features of local chronic
inflammation. An HS may form in as little as 2–10 wk after wound
closure. Induction of hypertrophy is followed by an activation
phase (AHS) with exacerbated symptoms that may persist for
months or years. In the subsequent remission phase (RHS), all the
symptoms decrease, the HS flattens and it eventually becomes stable
after months or even years (Stella et al, 1998). In addition,
immunologic parameters discriminate the different phases of the
hypertrophic scarring process. In comparison with RHS, AHS are
characterized by (i) an enhanced number of infiltrating T cells and
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analysis of AHS samples showed strong IL-15 immuno-
reactivity in keratinocytes and Langerhans cells in the
epidermis and in macrophages, fibroblasts, and dermal
dendritic cells in the dermis. High levels of IL-15
expression in AHS correlated with abundant infiltra-
tion of activated CD3Fcells. Ex vivo experiments
indicate that IL-15 can sustain the proliferative
response of T cells derived from AHS but not from
RHS and NTS. In addition, IL-15 prevents both
cytokine deprivation and activation-induced apoptosis
of T cells derived from AHS. Taken together, these
results suggest that IL-15 can be involved in the
recruitment, proliferation, and apoptosis inhibition of
T cells in AHS. The findings that the evolution from
an AHS to a RHS is associated with a decrease in IL15
expression, and with a loss of IL-15 responsiveness in
ex vivo-cultured T cells, indicate that this cytokine
plays an important role in the biology of pathologic
scar formation. J Invest Dermatol 113:238–245, 1999
macrophages in both epidermis and dermis (Castagnoli et al, 1997);
(ii) the ectopic expression of HLA class II (Castagnoli et al, 1990),
ICAM-1 (Castagnoli et al, 1994), IL-2R (Castagnoli et al, 1996),
and CD36 molecules on keratinocytes and fibroblasts (Alessio et al,
1998); and (iii) enhanced biosynthesis and expression of IFN-γ
(Stella et al, 1998).
Because HS can be readily monitored until complete regression,
they provide a good model for the study of inflammatory fibrotic
disorders; however, very little is known about the biologic mechan-
isms triggering the hypertrophic response and the shift from the
active to the remission phase.
IL-15, a cytokine identified on the basis of biologic activities
similar to IL-2, induces T and B cell proliferation, antibody
production, and generation of cytolytic effector cells (Burton et al,
1994; Grabstein et al, 1994; Armitage et al, 1995; Tagaya et al,
1996). Several studies have suggested that IL-15 is involved in
chronic inflammatory diseases or autoimmune disorders because it
is chemotactic for T cells (Wilkinson and Liew, 1995; McInnes
et al, 1996, 1997) and induces monocytes and polymorphonuclear
cells to secrete proinflammatory and chemotactic cytokines (Alleva
et al, 1997; Badolato et al, 1997; Musso et al, 1998). Whereas IL-
2 is produced only by activated T cells, IL-15 is expressed in a
variety of tissues and cell lines, including monocytes-macrophages,
dendritic cells, epithelial cell lines, keratinocytes, and fibroblasts
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(Grabstein et al, 1994; Bamford et al, 1996; Doherty et al, 1996).
The findings that IL-15 production by keratinocytes and dermal
fibroblasts can be modulated by UV radiation (Mohamadzadeh
et al, 1995) point to its involvement in photosensitive diseases of
the skin and in skin-related immune responses.
This paper investigates (i) IL-15 mRNA and protein expression
in AHS, RHS, normotrophic scars (NTS), and normal skin (NS);
(ii) the correlation between IL-15 expression and the number of
infiltrating T cells; and (iii) the effects of IL-15 on T cells that
infiltrate HS tissues.
MATERIALS AND METHODS
Patients Twenty-five males and 16 females from 13 to 69 years of age
(mean 40.7), discharged from the Turin Burn Center, were admitted to
the study after giving their informed consent. They had a mean total
burned surface area (TBSA%) of 32.3% (range 12%–90%) and a mean full
thickness burn of 18% (range 5%–50%). They were followed as outpatients
for at least 36 months and classified as NTS (nine cases) or HS (32). The
latter were further subdivided into AHS (19) and RHS (13). The terms
AHS, RHS that describe the clinical and immunologic features of their
evolution, have been previously proposed (Stella et al, 1998). All AHS
were elevated, erythematous, often painful: 11 patients also had various
degrees of skin retraction affecting articular motility. Telengectasias, small
bullae, and trophic ulcers were sometimes present. These active lesions
had not responded to continuous compressive therapy, massage, and
physiotherapy, and displayed no signs of regression 18 months after their
appearance. The RHS were flat, normochromic, and without dysaesthesias.
Biopsies were obtained from scars excised during plastic surgery carried out
under general anesthesia. No immunomodulation therapy was administered
before surgery. Control samples were specimens of nine consenting NTS
patients who underwent reconstructive surgery, and two NS specimens.
Immunohistochemistry Six millimeter punch biopsies of AHS, RHS,
NTS, and NS from different anatomical sites were obtained. IL-15
expression was evaluated in AHS specimens from different sites of the
body. To exclude possible errors depending on this variation, comparative
analyses were performed on RHS, NTS, and NS from the same part of
the body. At least two biopsies per patient were examined. Cryostat
sections were air-dried, acetone fixed, and incubated with primary mouse
monoclonal antibodies (MoAb) followed by avidin-biotin as previously
described (Griffiths et al, 1991). Staining was developed with 3-amino-9-
ethyl carbazole as a cromogen and the sections were then counterstained
with Mayer’s hematoxylin. For double immunolabeling, sections were
incubated in the first MoAb followed by a peroxidase-coupled secondary
antibody (Dako En Vision 1 TM, Dako, Glostrup, Denmark). 3-amino-
9-ethyl carbazole was used as cromogen. The second MoAb was detected
by the avidin-biotin alkaline phosphatase (Fast Blue BB salt as cromogen)
or by the avidin-biotin peroxidase system (4-chloro-2-naphtol as cromogen)
(Vector Laboratories, Burlingame, CA). Mouse antihuman MoAb used in
this study included: anti-IL-15 (M112; Genzyme, Cambridge, MA), anti-
CD3 (Leu-4; Becton-Dickinson, San Jose, CA), antimacrophage (clone
Ber-MAC3), antifibroblast (Clone 5B5), anti-CD1a (Dako). For negative
controls, the first MoAb was either omitted or replaced by an irrelevant
isotype-matched reagent. Specificity of MoAb M112 was confirmed by
complete neutralization of binding to sections following preincubation
with 50 ng r-IL-15 (Peprotech, Rocky Hill, NJ) per ml for 1 h at 37°C.
Slides were examined double-blindly and photographed using a Zeiss
Axiolab (Germany) microscope.
Quantitation of cells infiltrating scar tissues Stained cells were
separately counted in the epidermis, subpapillary dermis, and reticular
dermis on six or more sequential sections in at least eight random fields
measuring 0.25 mm2 at 3400 magnification. Activated T cells were
counted by staining the first section with anti-CD3 MoAb and the second
with either anti-HLA class II or anti-CD25 MoAb, and their percentages
were calculated as the ratio between cells positive for anti-HLA class II or
CD25 in the second section and those positive for anti-CD3 in the first.
Student’s t test was used for the statistical analysis.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
analysis Freshly harvested tissues were frozen in liquid nitrogen. Total
RNA extraction was performed with TRIzol (GIBCO/BRL, Life Techno-
logies, Grand Island, NY) according to the manufacturer’s instructions.
cDNA synthesis and PCR amplification were performed as previously
described (Musso et al, 1998). The following oligonucleotides were used
for PCR: IL-15 sense 59-GGATTTACCGTGGCTTTGAGTAATGAG-
39, IL-15 antisense 59-GAATCAATTGCAATCAAGAAGTG-39, with
cycles of 1 min at 94°C, 1 min 30 s at 65°C, and 2 min at 72°C, for
35 cycles; β-actin sense 59-GAGCGGGAAATCGTGCGTGACATT-39,
β-actin antisense 59-GAAGGTAGTTTCGTGGATGCC-39, with 27 of
the same cycles. A 15 µl sample of each PCR reaction was electrophoresed
through a 2% agarose gel and visualized with ethidium bromide.
Media Cells were cultured in RPMI 1640 medium containing penicillin,
streptomycin, gentamycin (Life Technologies) supplemented with 10%
heat-inactivated fetal calf serum (referred to hereafter as complete medium).
All the in vitro cultures were performed at 37°C in a humidified 5% CO2
atmosphere.
T lymphocyte cultures Biopsies from AHS, RHS, and NTS were
minced and immediately divided into two flasks containing complete
medium supplemented with either 100 U IL-2 (EuroCetus, Milan, Italy)
per ml or IL-15 (Peprotech). After 48 h, two suspensions containing
lymphocytes emigrated from dermis and epidermis were collected, separated
by density gradient centrifugation using Lymphoprep (Pharmacia, Uppsala,
Sweden) and stimulated (13106 cells per ml) with 2.5 µg PHA (Sigma,
St. Louis, MO) per ml. T lymphocytes were maintained in culture for
3 wk. IL-2 and IL-15 were replaced every 3 d. After 6 d, .97% of cells
were CD31 and TCRαβ1 as shown by flow cytometry. Short-term
cultures were set up with T cells from AHS cultured in the presence of
IL-2 as described. After 6 d, cells were recovered, washed twice, and
cultured (1 3 106 per ml) in the absence or presence of 100 U IL-2 per
ml or in the presence of 100 U IL-2 per ml plus 2.5 µg PHA per ml.
Parallel cultures were set up with lymphocytes from AHS cultured in the
presence of IL-15, then recovered and re-cultured in the absence or
presence of 100 U IL-15 per ml with or without 2.5 µg PHA per ml.
Flow cytometry For staining of membrane antigens, infiltrating T cells
cultured in the presence of IL-2 or IL-15 were recovered and labeled with
FITC-conjugated anti-Fas UB2 MoAb (Kamiya Biochemical, Thousand
Oaks, CA). For intracellular staining, 5 3 105 T cells were fixed,
permeabilized, and stained with FITC-conjugated anti-Bcl-2 MoAb (Dako)
or for DNA content as previously described (Novelli et al, 1997). Membrane
and internal antigens expression and DNA content were analyzed with a
FACScan flow cytometer (Becton-Dickinson, San Jose, CA). Each histo-
gram represents the results from 10,000 events.
RESULTS
IL-15 mRNA and protein expression in scar tissues The
specific expression of IL-15 mRNA was determined by RT-PCR
analysis in seven AHS, five RHS, six NTS, and two NS specimens.
As shown in Fig 1, a strong signal for IL-15 mRNA was observed
Figure 1. IL-15 mRNA expression. cDNA derived from NTS (lane 1),
NS (lane 4), RHS (lanes 2 and 3), and AHS (lanes 5 and 6) were amplified
with primers for IL-15 or β-actin, used as positive control.
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in AHS. Lower levels of IL-15 mRNA were present in RHS
tissues, whereas it was barely detectable in NTS and NS.
Semi-quantitative RT-PCR was also used to compare IL-15
mRNA expression in AHS, RHS, and NS biopsies from the same
patient. Sequential dilutions of cDNA were amplified. As shown
in Fig 2, the IL-15 signal in the NS sample disappeared at 1:2
dilution, whereas a positive signal was still observed at 1:16 in the
RHS and 1:32 in the AHS sample.
To verify the presence of IL-15 at the protein level, serial cryostat
sections from 19 AHS, 13 RHS, nine NTS, and two NS were
analyzed immunohistochemically with anti-IL-15 MoAb. Table I
shows that in the epidermis of AHS, keratinocytes and Langerhans
cells (CD11) were strongly positive for IL-15. The reactivity of
the anti-IL-15 MoAb on keratinocytes was localized in foci in the
basal layer and in the stratum granulosum and spinosum (Fig 3a).
The staining pattern (Fig 3b) indicates that they expressed intra-
cellular (i.e., synthesized) rather than membrane-bound IL-15.
Keratinocytes of RHS expressed significantly lower levels of IL-15
with the same tissue distribution pattern as AHS. In contrast, little
or no reactivity was observed in keratinocytes of NTS and NS
with anti-IL-15 MoAb (Table I, Fig 3d). Macrophages, fibroblasts,
and dermal dendritic cells (DDC) in the subpapillary dermis of
AHS were strongly IL-15 positive, whereas the reticular dermis
showed weaker staining (Table I, Fig 3c). The IL-15 positivity of
these cell types was significantly lower in RHS and NTS (Fig 3d),
and barely detectable in biopsies from NS. These data were further
confirmed by double staining using anti-IL-15 and MoAb against
CD1a, macrophages, and fibroblasts (Fig 4a–c). CD3 positive cells
did not express IL-15 (data not shown), as expected (Grabstein
et al, 1994). No significant variation in IL-15 expression among
Figure 2. IL-15 PCR amplification of cDNA sequential dilutions.
Dilution were 1:1, 1:2, 1:4, 1:16, 1:32 for AHS (A), RHS (B), and normal
skin (C) (left panel). Same dilutions were amplified for β-actin used as
positive control (right panel).
Table I. Immunohistochemical distribution of IL-15 in
scar tissuesa
Reticular dermis
Subpapillary Monocytes, Monocytes,
dermis dendritic dendritic
Epidermis Langerhans cells, cells,
Keratinocytes cells fibroblasts fibroblasts
AHS (N 5 19) 11 111 11111 111
RHS (N 5 13) 6 11 111 11
NTS (N 5 9) – 1 1 1
NS (N 5 2) – 1 1 1
aThe staining intensity of the scar was rated as –, 6, 1, 11, 111, 1111,
11111.
different anatomical sites was observed in any specimen groups
analyzed. Staining with anti-IL-15 MoAb was completely abolished
after its preincubation with recombinant human IL-15 (data not
shown).
Correlation between CD31 cells and IL-15
expression Because IL-15 is chemoattractant for T cells (Wilkin-
son and Liew, 1995) and because T cells are the most abundant
cell population infiltrating HS (Castagnoli et al, 1997), we investi-
gated the possibility of a correlation between their distribution and
IL-15 expression in HS (Table II). Immunohistochemical analysis
showed that the number of T cells infiltrating AHS was dramatically
higher than in RHS and NTS. The percentage of activated T cells
(HLA DR1; CD251) was ~70% in AHS compared with ~40% in
RHS and NTS, although the absolute number of T cells in the
epidermis was significantly lower than in the subpapillary and
reticular dermis. The distribution of activated T cells in AHS
correlated with increased IL-15 expression. CD31 lymphocytes
were present in clusters or as single cells near IL-15 positive
keratinocytes or Langerhans cells (Fig 3e, f, Fig 4d). In RHS and
NTS CD31 lymphocytes were less abundant (p , 0.001 and
p , 0.0001, respectively) and this decrease correlated with a lower
expression of IL-15.
Effect of IL-2 and IL-15 on ex vivo expansion of T lympho-
cytes from AHS, RHS, and NTS We studied the proliferative
response of T lymphocytes from AHS, RHS, and NTS biopsies
that were stimulated with PHA and kept in culture for 21 d by
the addition of IL-2 or IL-15. As shown in Fig 5, IL-2 and IL-15
were equally effective to stimulate the growth of T lymphocytes
derived from AHS. T lymphocytes from RHS responded only to
IL-2, those from NTS did not proliferate in the presence of either
IL-2 or IL-15.
Effect of IL-2 and IL-15 on apoptosis and cell cycle progres-
sion of T lymphocytes infiltrating HS Enhanced IL-15 in
AHS correlated with the increase in the number of infiltrating
T cells (see Table II), suggesting that this enhancement promotes
their recruitment, survival, and expansion. This possibility was
investigated by comparing the effects of IL-15 and IL-2 on cell
cycle progression and susceptibility to apoptosis following growth
factor deprivation and TCR stimulation, the two main events that
lead to a reduction in the number of activated T lymphocytes
(Lenardo, 1996). Both forms of apoptosis can be induced in vitro
by culturing activated T cells in the absence of cytokines or by
stimulating them with PHA in the absence of APC (Lenardo,
1996; Novelli et al, 1996, 1997). T cells from AHS and RHS were
expanded in the presence of IL-2 and subsequently cultured for
72 h without IL-2 or in the presence of 100 U IL-2 per ml, with
or without 2.5 µg PHA per ml. In parallel cultures, IL-15 was
used in place of IL-2 at the same concentration; however, having
reported here that T cells from RHS do not respond to IL-15 (see
Fig 5), cell cycle analysis was limited to RHS T cells expanded in
the presence of IL-2.
As shown in Table III, HS T cells cultured without IL-2 were
mostly in G0/G1, with a significant number (~10%) in apoptosis.
In the presence of IL-2, a major difference between RHS and
AHS T cells was observed: in the latter the number of cells in G0/
G1 was greatly decreased and those in S 1 G2/M considerably
increased. PHA decreased the G0/G1 cohort in both RHS and AHS
T cells and massively increased the percentage of apoptotic cells.
IL-15-expanded AHS T cells cultured without IL-15 were
mostly in G0/G1 (~65%), the remainder being prevalently apoptotic
(~34%) (Table III). The addition of IL-15 reduced the number of
cells in G0/G1 (~47%) and drastically reduced the number of cells
in apoptosis (~5%), while increasing the cohort in S 1 G2/M to
a ~48%.
Effect of IL-2 and IL-15 on Bcl-2 expression of T lympho-
cytes infiltrating HS Because IL-2 and IL-15 have been reported
to protect T cells from apoptosis by upmodulating Bcl-2 expression
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Figure 3. Photomicrographs stained by means of a biotin-avidin-peroxidase technique with MoAb in scar tissues. (a, b) Epidermis of AHS
stained with anti-IL-15 MoAb. Several positive keratinocytes and foci of strongly positive Langerhans cells can be seen. Keratinocytes express intracellular
(b) rather than membrane-bound IL-15. (a, magnification 3400, calibration bar 24 µm; b, magnification 31000, calibration bar 9.6 µm.) (c) AHS section
stained with anti-IL-15 MoAb. The positivity is widely distributed in the subpapillary dermis, whereas it is less evident in the reticular dermis; positive
keratinocytes are localized in foci. (d) NTS stained with anti-IL-15 MoAb. Keratinocytes are negative and few positive infiltrating cells can be observed.
(e, f) AHS serial sections stained with anti-CD3 MoAb and anti-IL-15 MoAb, respectively. Nearby keratinocytes show strong IL-15 expression (f). There
are many CD31 cells present in cluster in the epidermis and in the subpapillary dermis (e). (c–f magnification 3100, calibration bar 96 µm.)
(Akbar et al, 1996), the effects of these cytokines on the expression
of Bcl-2 in HS T cells were evaluated by immunofluorescence. As
shown in Table III, IL-2 upregulated Bcl-2 expression in both
RHS and AHS, but in AHS IL-15 proved to be a more potent
inducer of Bcl-2. Immunofluorescence analysis of the expression
of Fas, a molecule that transduces the apoptotic signal in T cells
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Figure 4. Photomicrographs of double-immunolabeled AHS sections. (a) Intracellular IL-15 expression (red) in CD1a positive cells (blue dark).
Peroxidase-coupled secondary antibody (for IL-15)/avidin-biotin peroxidase (for CD1a) procedures. (b) IL-15 expression in macrophages. IL-15 positive
cells (red), macrophages (blue), and double labeled macrophages (purple). Peroxidase-coupled secondary antibody (for IL-15)/avidin-biotin alkaline
phosphatase (for macrophages) procedures. (c) IL-15 expression (red) on fibroblasts (blue). Peroxidase-coupled secondary antibody (for IL-15)/avidin-
biotin alkaline phosphatase (for fibroblasts) procedures. (d) Cluster of CD3 positive cells (red) are present nearby the Langerhans cells (blue dark) in the
epidermidis of AHS. Peroxidase-coupled secondary antibody (for CD3)/avidin-biotin peroxidase (for CD1a) procedures. (a, c magnification 31000,
calibration bar 9.6 µm; b, d magnification 3400, calibration bar 24 µm.)
Table II. Immunohistochemical analysis of infiltrating CD3F cells, their activation state, and IL-15 expression in post-
burn scar tissue
Epidermis Subpapillary dermis Reticular dermis
CD31a % activated IL-15 CD31 % activated IL-15 CD31 % activated IL-15
T cells T cells T cells
AHS (N 5 19) 10 6 9 69 6 11 11 135 6 60 71 6 14 11111 77 6 38 69 6 9 111
RHS (N 5 13) 4 6 3 39 6 20 6 54 6 20 44 6 23 11 47 6 20 42 6 21 1
NTS (N 5 9) 2 6 2 34 6 12 – 40 6 3 37 6 21 1 27 6 6 36 6 17 6
aValues represent the number of CD31 cells counted in an 0.25 mm2 area. At least eight high-power fields were counted for each section.
bValues represent the percentage of cells positive for HLA DR and IL-2Rα evaluated as described in Materials and Methods.
cArbitrary intensity of IL-15 staining was rated as –, 6, 1, 11, 111, 1111, 11111.
(Nagata and Goldsein, 1998), was much the same on IL-2 and IL-
15 expanded AHS T cells and IL-2 expanded RHS T cells (data
not shown).
DISCUSSION
Our results indicate that IL-15 mRNA and protein are highly
expressed in AHS. In contrast, low expression of IL-15 is found
in RHS and it is barely detectable in NTS and NS, suggesting that
an increased expression of IL-15 is a feature of the active phase of
HS. AHS staining showed that IL-15 is produced by keratinocytes
and Langerhans cells in the epidermis, and by macrophages,
fibroblasts, and DDC in the dermis. Lower amounts of IL-15 were
detectable in RHS keratinocytes, macrophages, and fibroblasts.
Reactivity for IL-15 in RHS and NTS macrophages, fibroblasts,
and DDC was low. No staining was detectable in NTS and NS
keratinocytes.
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IL-15 mRNA is found in placenta, skeletal muscle, kidney, lung,
and heart, as well as in epithelial cells, DDC. and monocytes
(Grabstein et al, 1994; Bamford et al, 1996; Doherty et al, 1996;
Jonuleit et al, 1997). It has also been reported in dermal fibroblasts,
whereas its presence in keratinocytes and Langerhans cells is
uncertain (Mohamadzadeh et al, 1995; Blauvelt et al, 1996).
Although IL-15 mRNA is induced in vitro by a variety of stimuli,
IL-15 protein is usually not detectable in supernatants, probably
because its secretion is tightly regulated at the post-translational
level. In fact, IL-15 translation is impeded by the presence of
attenuation sites in the 59 untranslated region of the mRNA and
an atypical signal peptide (Bamford et al, 1996, 1998; Onu et al,
1997; Tagaya et al, 1997; Nishimura et al, 1998). In vivo IL-15,
however, has been identified in chronic inflammatory diseases and
autoimmune disorders. In synovial tissue from rheumatoid arthritis
(RA) patients and in alveolar macrophages of sarcoidosis patients,
IL-15 has been identified by immuno-cytochemistry; in RA
synovial fluid, significant levels of IL-15 have been detected by
ELISA (McAdam et al, 1996; Agostini et al, 1996). Taken together,
our results demonstrate that IL-15 mRNA and protein are present
in the skin tissues, and that its expression is increased in HS,
suggesting its involvement in pathologic scarring.
Figure 5. Effect of IL-2 and IL-15 on ex vivo growth of T lymphocytes
infiltrating AHS, RHS, and NTS tissues. T cells from biopsies were
stimulated with 2.5 µg PHA per ml and cultured in 24 well microtest
plates (1 3 105 per ml) in complete medium containing 100 U IL-2 per
ml (left panel) or IL-15 (right panel). At the indicated times, a small aliquot
of the cell suspension was removed, mixed with an equal volume of trypan
blue-containing solution, and viable cells were counted. The results are
expressed as the arithmetic mean of 1 SD of cell number from triplicate
cultures. The experiments were performed independently at least three
times and representative experiments are shown.
Table III. Effect of IL-2 and IL-15 on AHS and RHS T lymphocytes apoptosis, cell cycle progression, and Bcl-2
expression
Perentage of cellsc
T cells expansion T cells re-culture
stimulusa stimulusb Apoptosis G0/G1 S 1 G2/M Bcl-2 expression
d (FMI)
RHS IL-2 Medium 8 90 2 100
IL-2 3 85 12 135
IL2 1 PHA 25 41 34 NDe
AHS IL-2 Medium 12 87 1 85
Il-2 6 65 29 103
IL2 1 PHA 31 34 35 ND
AHS IL-15 Medium 34 65 1 81
IL-15 5 47 48 156
IL15 1 PHA 8 59 33 ND
aT cells from AHS and RHS were obtained from biopsies, activated with PHA in the presence of 100 U IL-2 per ml or 100 U IL-15 per ml and expanded for 6 d as
described in Materials and Methods.
bT cells expanded in IL-2 or IL-15 were recovered, washed, and re-cultured (1 3 106 per ml) in complete medium without IL-2 or IL-15, with IL-2 or IL-15, or with
IL-2 or IL-15 plus 2.5 µg/PHA per ml.
cThe percentage of cells in the different phases of the cell cycle was evaluated using propidium iodide staining and cytofluorimetry after 72 h culture. The experiments
were performed independently at least three times and a representative experiment is shown.
dValues are referred to cytofluorimetric assessment of the Bcl-2 Fluorescence Mean Intensity (FMI) after 72 h culture. FMI was calculated by subtracting the fluorescence
mean of the FITC-conjugated isotype-control IgG MoAb to that of FITC-conjugated anti-Bcl-2 MoAb.
eNot determined.
IL-15 uses the β and γ chains of the IL-2R as well as an IL-15-
specific α chain to exert its function (Anderson et al, 1995; Giri
et al, 1995). Like IL-2, IL-15 induces T cell proliferation and acts
as a potent T cell chemoattractant (McInnes et al, 1996; McInnes
et al, 1997). In RA, locally produced IL-15 recruits and activates
synovial T cells. Whereas monocytes and PMN are also detected
(Castagnoli et al, 1997), our results show that CD31, IL-2Rα1,
and HLA DR1 cells constitute the major component of the
leukocyte infiltrate in HS and that there is a straightforward
correlation between the increase of IL-15 protein expression and
the number of infiltrating T cells, pointing to their recruitment by
IL-15.
Skin cells produce numerous cytokines, some of which are
chemotactic (Kovacs, 1991; Uyemura et al, 1993; Bruch-Gerharz
et al, 1996). For example, IL-8 and MCP-1 were initially isolated
as neutrophil and monocyte chemoattractants, but they are also
chemotactic for T cells and could be involved in their recruitment
(Kelvin et al, 1993; Larsen et al, 1989; Koch et al, 1992; Baggiolini
et al, 1994; Carr et al, 1994). Our recent demonstration that IL-15
stimulates monocytes to secrete IL-8 and MCP-1 (Badolato et al,
1997) suggests that its T cell chemotaxis may be direct or mediated
by the induction of these chemokines. Unlike other T cell
chemokines, however, IL-15 is also associated with lymphocyte
proliferation. Increased IL-15 production in AHS may have import-
ant consequences for the fate of infiltrating T lymphocytes: our
findings suggest that it may favor their migration and activation at
AHS sites. The effects of IL-2 and IL-15 on T cells overlap.
Whereas IL-2 is mainly produced by T cells, IL-15 is produced by
nonlymphoid cells including monocytes and macrophages
(Grabstein et al, 1994). Our data suggest that the local production
of IL-15 by fibroblasts and keratinocytes in early HS induces the
infiltration of T cells and maintains their proliferative response
when T cells lose their ability to respond to IL-2. In fact, IL-2 is
the main autocrine factor driving T cell growth and its consumption
throughout their expansion leads to growth factor deprivation-
induced apoptosis if no other costimulatory factors are present
(Smith, 1998). The fact that IL-15 is produced by AHS suggests
that this cytokine could provide a paracrine signal prolonging the
survival of infiltrating T lymphocytes. In agreement with our
hypothesis, it has recently been published that IL-15 behaves as an
autocrine/paracrine viability factor for cutaneous T-cell lymphoma
cells (CTCL). As in AHS, IL-15 protein was detected in skin
sections from CTCL patients (Dobbeling et al, 1998). These
observations closely fit our data that demonstrate, by immunohisto-
chemistry and RT-PCR, that IL-15 expression is strongly enhanced
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in AHS. In addition, these findings suggest that IL-15 could be
involved in the induction of T cells recruitment and proliferation.
Therefore, HS remission might depend on the cessation or decrease
of IL-15 production.
As we reported, the number of T cells infiltrating RHS and
NTS was much lower than in AHS; this constituted a bias for our
experiments because we could not recover a sufficient number of
emigrated cells for our functional assays; however, we observed a
differential ability of PHA-activated T cells derived from AHS to
proliferate in response to IL-15 and IL-2 as compared with mitogen-
activated T cells derived from RHS and NTS biopsies in all of the
ex vivo experiments performed. In fact, while we could always
detect a proliferative response of T cells from AHS to both IL-2
and IL-15, T cells derived from RHS responded only to IL-2 but
not to IL-15. Conversely, NTS T cells did not respond either to
IL-2 or to IL-15. The lack of proliferative response of T cells
derived from RHS to IL-15 might reflect a reduced expression of
IL-15R or a functional impairment of cell response to the cytokine.
The differential proliferative response to IL-2 and/or IL-15 by
T cells derived from RHS and AHS was detected after the first
week of ex vivo culture but became more evident after the following
2 wk of culture, suggesting that T cell stimulation by PHA did not
affect the functional properties of T cells recovered from HS.
The ability of IL-15 to sustain the proliferative response of
T cells infiltrating AHS was further supported by demonstrating
that IL-15 could upregulate Bcl-2 expression of cultured T cells
and inhibit apoptosis induced by cytokine deprivation or by
activation. IL-2 was effective to stimulate AHS T cells to enter
into S 1 G2/M phases, as compared with RHS T cells, but could
not prevent PHA activation-induced apoptosis in both RHS and
AHS T cells. In contrast, IL-15 was more effective than IL-2 in
the enhancement of T cells proliferation, in the prevention of
apoptosis, and in the induction of Bcl-2 expression in AHS
infiltrating T cells, as compared with IL-2. These data are in
agreement with previous reports that IL-15 upregulates the expres-
sion of Bcl-2 and protects activated T cells from apoptosis induced
by several stimuli such as anti-Fas MoAb, TCR triggering, dexa-
methasone, and IL-2 withdrawal (Akbar et al, 1996; Bulfone-Paus
et al, 1997). In addition, it has been shown that the resolution of
a T cell-mediated cutaneous inflammation such as the Mantoux
reaction is largely dependent on the decrease of IL-15 and IL-2
expression in the skin tissues and thereby of apoptosis of infiltrating
T cells (Orteu et al, 1998).
The progress from AHS to RHS is apparently an outcome of
the active or passive apoptosis of activated infiltrating T cells
resulting from decreased IL-15 production. The soundness of this
hypothesis is currently being investigated in our laboratory. In
conclusion, this study provides evidence of the presence of IL-15
in pathologic scar formation. Our findings indicate that it recruits,
activates, and prevents apoptosis of activated T lymphocytes in
AHS. Administration of IL-15 or IL-15 receptor inhibitors could
thus provide a new form of HS management.
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